Press Releases

TheraVet announces the commercial launch of BIOCERA-VET

 

April 01, 2021

 

TheraVet S.A., a pioneering company in the management of osteoarticular diseases in pets, announced today the commercial launch of BIOCERA-VET, its new generation bone substitute for the treatment of bone surgeries in small companions. BIOCERA-VET will initially be commercialized on the Belgian orthopedic market and will quickly be extended to France and the Netherlands. Due to the growing importance of pets and of their quality of life for their owners, animal health is becoming more and more a social and medical issue ...

 

 

Read more

 

 

 

PREVIOUS PRESS RELEASES

 

 

 

Positive results of a single intra-articular injection of VISCO-VET in canine osteoarthritis

Positive results in canine cranial cruciate ligament deficiency



TheraVet raises 4 M€  to accelerate the development of its two veterinary products

March 04, 2021

 

TheraVet S.A., a pioneering company in the management of osteoarticular diseases in pets, announced today positive results for its study evaluating VISCO-VET, its injectable visco-regenerative gel, in the prevention and treatment of osteoarthritis in a canine model of the disease. Osteoarthritis (OA) is a progressive degenerative joint disease characterized by a loss of joint cartilage...

 

Read more

January 26, 2021

 

TheraVet S.A., a pioneering company in the osteoarticular diseases of the companion animals, announced today the positive results of VISCO-VET, its injectable visco-regenerating gel, in the prevention of cranial cruciate ligament (CCL) deficiency in canine model of cranial cruciate ligament deficiency. CCL deficiency is one of the most important cause of stifle (knee) instability and lameness...

 

 

Read more

December 10, 2020

 

TheraVet S.A., the specialist of the osteo-articular diseases in small companion animals, announces today that it will raise by the end of 2020 €4 million of additional funding for the development of its innovative veterinary product lines. This funding consists of a capital increase of €1.9 million realized with TheraVet's historical shareholders...

 

 

 

Read more

TheraVet launches a prospective multicentric clinical trial in canine osteosarcoma

 

TheraVet completes first regulatory milestones for the US registration (NADA) of VISCO-VET in canine osteoarthritis


TheraVet starts its US operations in its Texas-based subsidiary

 


 November 17, 2020

 

Read more


 June 15, 2020

 

Read more


 November 07, 2019

 

Read more

 

This website uses cookies The website of TheraVet SA uses functional cookies. In case of analysing our traffic or advertising, we also place cookies that share information about your use of our site with our analytics partners, our social media and advertising partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Show details Hide details
Allow selection Allow all cookies